Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL — Stella

Home/Chronic Lymphocytic Leukemia/

View on ClinicalTrials.gov

Recruiting

Back to Chronic Lymphocytic Leukemia trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

M D Anderson Cancer Center, Houston, Texas

Key details

Phase

Safety & dosing

Sponsor

M.D. Anderson Cancer Center

Enrollment target

~90 participants

Started

June 2017

Primary completion

May 2027

Age range

18 Years and older

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.